Early observations and pilot data that first suggested a new direction
Chronic myeloid leukemia (CML) was a uniformly fatal disease with a median survival of 3-5 years before the molecular era. Treatment options were limited to interferon-alpha (which achieved cytogenetic responses in ~15-25% but with significant toxicity) and allogeneic bone marrow transplantation (curative but limited by donor availability and transplant-related mortality of 15-30%). The identification of the BCR-ABL fusion oncogene as the driving molecular event, resulting from the Philadelphia chromosome translocation t(9;22), provided the therapeutic target. Brian Druker's work developing imatinib (STI571), a selective BCR-ABL tyrosine kinase inhibitor, produced dramatic hematologic and cytogenetic responses in a phase 1 trial published in 2001.
Landmark RCTs and pivotal trials that established the evidence base
The IRIS (International Randomized Study of Interferon and STI571) trial, published in the NEJM in 2003, randomized 1,106 patients with newly diagnosed CML-CP to imatinib 400 mg daily versus interferon-alpha plus cytarabine. Imatinib achieved a complete cytogenetic response rate of 76% vs 15%, with far superior tolerability. The trial was effectively stopped early due to overwhelming imatinib superiority. Long-term follow-up showed 8-year overall survival of 85% and event-free survival of 81%. IRIS transformed CML from a fatal disease to a manageable chronic condition and established the paradigm for targeted therapy in oncology. Imatinib received FDA approval in 2001 based on accelerated review.
Follow-up studies, subgroup analyses, and real-world validation
Second-generation TKIs were developed to address imatinib resistance (occurring in 20-30% of patients, often via BCR-ABL kinase domain mutations) and to achieve deeper molecular responses. The ENESTnd trial showed nilotinib achieved significantly higher rates of major molecular response (MMR) than imatinib at 12 months. DASISION demonstrated similar superiority for dasatinib. Both were approved as first-line options. The concept of treatment-free remission (TFR) emerged when the STIM (Stop Imatinib) trial showed that approximately 40% of patients in sustained deep molecular response (DMR) could safely discontinue TKI therapy without relapse. The EURO-SKI trial confirmed this across a larger European cohort. Asciminib, a first-in-class STAMP inhibitor targeting the ABL myristoyl pocket, showed superiority over bosutinib in the ASCEMBL trial for resistant CML.
Integration into clinical practice guidelines and recommendations
NCCN and ELN (European LeukemiaNet) 2020 guidelines provide comprehensive TKI selection and monitoring frameworks. First-line options include imatinib, nilotinib, dasatinib, and bosutinib, with selection based on risk score, comorbidities, and side effect profiles. Molecular monitoring by RT-qPCR at 3, 6, and 12 months with defined response milestones guides therapy optimization. Treatment-free remission is now an explicit treatment goal, with defined criteria for attempting TKI discontinuation: sustained deep molecular response (MR4 or better) for at least 2 years, access to reliable molecular monitoring, and willingness to restart if molecular relapse occurs.
ELN Recommendations for Management of CML
First-line TKI selection guided by risk score and comorbidities. Molecular response milestones at 3, 6, 12 months define optimal, warning, and failure categories. Treatment-free remission can be attempted after sustained DMR >=2 years with monthly molecular monitoring for first 12 months off therapy.
NCCN Clinical Practice Guidelines: CML
Imatinib, nilotinib, dasatinib, or bosutinib for first-line chronic phase CML. Asciminib for patients failing >=2 prior TKIs. TFR attempt appropriate for patients in sustained MR4 >=2 years. Ponatinib or asciminib for T315I mutation.
Now
Current standard of care and ongoing research directions
CML has been transformed from a fatal disease to one where patients have near-normal life expectancy on TKI therapy and many can achieve drug-free remission. The treatment landscape includes five approved first-line TKIs plus asciminib for resistant disease. Treatment-free remission is achievable in 40-60% of patients who attempt discontinuation after sustained deep molecular response, with most relapses occurring within 6 months and responding promptly to TKI re-initiation. Current frontiers include upfront combination strategies (TKI plus interferon) to increase TFR rates, generic imatinib improving global access, and emerging research on whether CML can be functionally cured by eliminating leukemic stem cells. The T315I gatekeeper mutation is now addressable with ponatinib and asciminib.
How did imatinib change the natural history of CML?+
Before imatinib, CML had a median survival of 3-5 years and inevitably progressed to fatal blast crisis. The IRIS trial showed imatinib achieved 8-year overall survival of 85%, transforming CML into a chronic disease. Patients diagnosed today on TKI therapy have near-normal life expectancy, and many can achieve treatment-free remission.
What is treatment-free remission in CML?+
Treatment-free remission (TFR) is the ability to discontinue TKI therapy while maintaining undetectable or very low BCR-ABL levels. Approximately 40-60% of patients in sustained deep molecular response for >=2 years can successfully stop treatment. Monthly molecular monitoring for the first year is mandatory, and most who relapse do so within 6 months and respond to TKI restart.
When should second-generation TKIs be preferred over imatinib as first-line?+
Second-generation TKIs (nilotinib, dasatinib) achieve faster and deeper molecular responses than imatinib and are preferred for higher-risk patients (Sokal/ELTS intermediate/high risk). However, each has distinct toxicities (nilotinib: cardiovascular, dasatinib: pleural effusions) that must be matched to patient comorbidities. Generic imatinib remains appropriate for low-risk patients and in resource-limited settings.
